$OGN
Organon & Co.

2024 Q2 Form 10-Q Financial Statement

#000182182524000056 Filed on May 03, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $1.607B $1.622B
YoY Change -0.06% 5.46%
Cost Of Revenue $668.0M $665.0M
YoY Change 4.38% 14.66%
Gross Profit $939.0M $957.0M
YoY Change -3.0% -0.1%
Gross Profit Margin 58.43% 59.0%
Selling, General & Admin $437.0M $431.0M
YoY Change -3.1% -0.92%
% of Gross Profit 46.54% 45.04%
Research & Development $116.0M $112.0M
YoY Change -9.38% -13.18%
% of Gross Profit 12.35% 11.7%
Depreciation & Amortization $66.00M $32.00M
YoY Change 13.79% 14.29%
% of Gross Profit 7.03% 3.34%
Operating Expenses $553.0M $543.0M
YoY Change -4.49% -3.72%
Operating Profit $386.0M $414.0M
YoY Change -0.77% 5.08%
Interest Expense $131.0M $131.0M
YoY Change -0.76% -0.76%
% of Operating Profit 33.94% 31.64%
Other Income/Expense, Net
YoY Change
Pretax Income $235.0M $236.0M
YoY Change -7.48% 0.43%
Income Tax $40.00M $35.00M
% Of Pretax Income 17.02% 14.83%
Net Earnings $195.0M $201.0M
YoY Change -19.42% 13.56%
Net Earnings / Revenue 12.13% 12.39%
Basic Earnings Per Share $0.76 $0.78
Diluted Earnings Per Share $0.75 $0.78
COMMON SHARES
Basic Shares Outstanding 257.2M shares 255.6M shares
Diluted Shares Outstanding 258.6M shares 258.4M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $704.0M $575.0M
YoY Change 115.95% 25.27%
Cash & Equivalents $704.0M $575.0M
Short-Term Investments
Other Short-Term Assets $901.0M $811.0M
YoY Change 18.4% 7.42%
Inventory $1.287B $1.263B
Prepaid Expenses
Receivables $1.617B $1.547B
Other Receivables $0.00 $0.00
Total Short-Term Assets $4.509B $4.196B
YoY Change 13.92% 11.01%
LONG-TERM ASSETS
Property, Plant & Equipment $1.162B $1.180B
YoY Change 4.68% 11.85%
Goodwill $4.603B $4.603B
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.196B $1.194B
YoY Change 67.04% 69.6%
Total Long-Term Assets $7.645B $7.695B
YoY Change 8.89% 10.2%
TOTAL ASSETS
Total Short-Term Assets $4.509B $4.196B
Total Long-Term Assets $7.645B $7.695B
Total Assets $12.15B $11.89B
YoY Change 10.7% 10.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.243B $955.0M
YoY Change 11.48% -4.12%
Accrued Expenses $1.302B $1.385B
YoY Change 18.26% 20.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $9.000M $9.000M
YoY Change 12.5% 12.5%
Total Short-Term Liabilities $2.755B $2.545B
YoY Change 15.42% 8.48%
LONG-TERM LIABILITIES
Long-Term Debt $8.647B $8.705B
YoY Change -0.86% 0.02%
Other Long-Term Liabilities $548.0M $549.0M
YoY Change 39.44% 30.4%
Total Long-Term Liabilities $9.195B $9.254B
YoY Change 0.88% 1.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.755B $2.545B
Total Long-Term Liabilities $9.195B $9.254B
Total Liabilities $12.01B $11.84B
YoY Change 4.13% 3.25%
SHAREHOLDERS EQUITY
Retained Earnings $690.0M $573.0M
YoY Change -2860.0% -378.16%
Common Stock $66.00M $52.00M
YoY Change 2100.0% 1633.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $144.0M $48.00M
YoY Change
Total Liabilities & Shareholders Equity $12.15B $11.89B
YoY Change 10.7% 10.48%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income $195.0M $201.0M
YoY Change -19.42% 13.56%
Depreciation, Depletion And Amortization $66.00M $32.00M
YoY Change 13.79% 14.29%
Cash From Operating Activities $332.0M $76.00M
YoY Change 1129.63% -33.33%
INVESTING ACTIVITIES
Capital Expenditures $47.00M $46.00M
YoY Change -33.8% 0.0%
Acquisitions
YoY Change
Other Investing Activities $1.000M -$50.00M
YoY Change 0.0%
Cash From Investing Activities -$46.00M -$96.00M
YoY Change -34.29% 77.78%
FINANCING ACTIVITIES
Cash Dividend Paid $70.00M
YoY Change -4.11%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $2.000M
YoY Change -99.21%
Cash From Financing Activities -134.0M -$74.00M
YoY Change 52.27% -77.3%
NET CHANGE
Cash From Operating Activities 332.0M $76.00M
Cash From Investing Activities -46.00M -$96.00M
Cash From Financing Activities -134.0M -$74.00M
Net Change In Cash 152.0M -$118.0M
YoY Change -216.03% -52.23%
FREE CASH FLOW
Cash From Operating Activities $332.0M $76.00M
Capital Expenditures $47.00M $46.00M
Free Cash Flow $285.0M $30.00M
YoY Change -747.73% -55.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2024Q1 us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2023Q1 us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2024Q1 us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2023Q1 us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2024Q1 us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2023Q1 us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2024Q1 us-gaap Derivative Gain Loss Statement Of Income Or Comprehensive Income Extensible Enumeration
DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
665000000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
580000000 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
431000000 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
435000000 usd
CY2024Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
112000000 usd
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
129000000 usd
CY2024Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
15000000 usd
CY2023Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
8000000 usd
CY2024Q1 us-gaap Restructuring Charges
RestructuringCharges
23000000 usd
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
4000000 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
131000000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
132000000 usd
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6000000 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-9000000 usd
CY2024Q1 ogn Other Operating And Nonoperating Income Expense
OtherOperatingAndNonoperatingIncomeExpense
-3000000 usd
CY2023Q1 ogn Other Operating And Nonoperating Income Expense
OtherOperatingAndNonoperatingIncomeExpense
-6000000 usd
CY2024Q1 ogn Costs Expenses And Other
CostsExpensesAndOther
1386000000 usd
CY2023Q1 ogn Costs Expenses And Other
CostsExpensesAndOther
1303000000 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
236000000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
235000000 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
58000000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
201000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
177000000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.78
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.69
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
255695000 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
254392000 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
258362000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
256170000 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
201000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
177000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
-1000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
0 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-37000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
30000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-36000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
30000000 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
165000000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
207000000 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
575000000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
693000000 usd
CY2024Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
11000000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
9000000 usd
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1547000000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1744000000 usd
CY2024Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
101000000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
110000000 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
1263000000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1315000000 usd
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
811000000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
756000000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
4196000000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4508000000 usd
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1180000000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1183000000 usd
CY2024Q1 us-gaap Goodwill
Goodwill
4603000000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
4603000000 usd
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
718000000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
533000000 usd
CY2024Q1 us-gaap Deferred Income Taxes And Other Assets Noncurrent
DeferredIncomeTaxesAndOtherAssetsNoncurrent
1194000000 usd
CY2023Q4 us-gaap Deferred Income Taxes And Other Assets Noncurrent
DeferredIncomeTaxesAndOtherAssetsNoncurrent
1231000000 usd
CY2024Q1 us-gaap Assets
Assets
11891000000 usd
CY2023Q4 us-gaap Assets
Assets
12058000000 usd
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
9000000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9000000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
955000000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1314000000 usd
CY2024Q1 ogn Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
1385000000 usd
CY2023Q4 ogn Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
1389000000 usd
CY2024Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
196000000 usd
CY2023Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
206000000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2545000000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2918000000 usd
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8705000000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8751000000 usd
CY2024Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
44000000 usd
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
47000000 usd
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
549000000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
412000000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
11843000000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
12128000000 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
255847000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
255847000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
255626000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
255626000 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
3000000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000000 usd
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49000000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
25000000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
573000000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
443000000 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-577000000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-541000000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
48000000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-70000000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11891000000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12058000000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-892000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
177000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
30000000 usd
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.28
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
73000000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21000000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-737000000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-70000000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
201000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-36000000 usd
CY2024Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.28
CY2024Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
71000000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24000000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
48000000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
201000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
177000000 usd
CY2024Q1 us-gaap Depreciation
Depreciation
32000000 usd
CY2023Q1 us-gaap Depreciation
Depreciation
28000000 usd
CY2024Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
33000000 usd
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
29000000 usd
CY2024Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
15000000 usd
CY2023Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Fair Value Acquired
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired
8000000 usd
CY2024Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
5000000 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3000000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
26000000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
22000000 usd
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
18000000 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2000000 usd
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-5000000 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-8000000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-163000000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-39000000 usd
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-19000000 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
38000000 usd
CY2024Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
57000000 usd
CY2023Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
3000000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-349000000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-139000000 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-15000000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-47000000 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-6000000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
6000000 usd
CY2024Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-22000000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-19000000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
76000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
114000000 usd
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46000000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46000000 usd
CY2024Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 usd
CY2023Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
8000000 usd
CY2024Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
50000000 usd
CY2023Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-96000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-54000000 usd
CY2024Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2000000 usd
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
252000000 usd
CY2024Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2000000 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1000000 usd
CY2024Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
70000000 usd
CY2023Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
73000000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-74000000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-326000000 usd
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-24000000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19000000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-118000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-247000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
693000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
706000000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
575000000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
459000000 usd
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
Background and Nature of Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organon &amp; Co. (“Organon” or the “Company”) is a global health care company with a focus on improving the health of women throughout their lives. Organon develops and delivers innovative health solutions through a portfolio of prescription therapies and medical devices within women’s health, biosimilars and established brands (the “Organon Products”). Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. The Company sells these products through various channels including drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom. Unless otherwise indicated, trademarks appearing in italics throughout this document are trademarks of, or are used under license by, the Organon group of companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operations include the following product portfolios:</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Women’s Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Organon’s women’s health products are sold by prescription primarily in two therapeutic areas, contraception, with key brands such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (etonogestrel implant) (sold as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implanon NXT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™ in some countries outside the United States) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NuvaRing® </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(etonogestrel / ethinyl estradiol vaginal ring), and fertility, with key brands such as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Follistim AQ®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (follitropin beta injection) (marketed in most countries outside the United States as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puregon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nexplanon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a long-acting reversible contraceptive, which is a class of contraceptives that is recognized as one of the most effective types of hormonal contraception available to patients with a low long-term average cost. Other women’s health products include the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">® System, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted, and a license from Daré Biosciences for the global commercial rights to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xaciato</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">® (clindamycin phosphate vaginal gel, 2%), an FDA-approved medication for the treatment of bacterial vaginosis (“BV”) in females 12 years of age and older. In October 2023, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xaciato </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was launched in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Biosimilars</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Organon’s current portfolio spans across immunology and oncology treatments. Organon’s oncology biosimilars; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ontruzant®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (trastuzumab-dttb) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aybintio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bevacizumab), have been launched in more than 20 countries and Organon’s immunology biosimilars; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Brenzys</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (etarnarcept), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renflexi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (infliximab-abda) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hadlima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (adalimumab-bwwd), have been launched in five countries. All five biosimilars in Organon’s portfolio have launched in Canada, and three biosimilars:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ontruzant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renflexis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hadlima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have launched in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Established Brands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Organon has a portfolio of established brands, which generally are beyond market exclusivity, including leading brands in cardiovascular, respiratory, dermatology and non-opioid pain management. A number of Organon’s established brands lost exclusivity years ago and have faced generic competition for some time.</span></div>
CY2024Q1 ogn Number Of Medicines And Products
NumberOfMedicinesAndProducts
60 medicineandproduct
CY2024Q1 ogn Number Of Manufacturing Facilities
NumberOfManufacturingFacilities
6 manufacturingfacility
CY2024Q1 us-gaap Basis Of Accounting
BasisOfAccounting
Basis of Presentation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by GAAP for complete consolidated financial statements are not included herein. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. All intercompany transactions and accounts within Organon have been eliminated. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Organon’s Annual Report on Form 10-K for the year ended December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in the Annual Report on Form 10-K for the year ended December 31, 2023. Accordingly, actual results could differ materially from management’s estimates and assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disaggregated information about a reporting entity’s </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on January 1, 2025, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. This ASU will have no impact on the Company’s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its income tax disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. The amendments in this ASU are effective for annual periods beginning on January 1, 2024 and interim periods beginning on January 1, 2025, and should be applied on a retrospective basis for all periods presented. This ASU will have no impact on the Company’s consolidated financial condition or results of operations. The Company is currently evaluating the impact to its segment disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Securities and Exchange Commission (“SEC”) Final Rules Not Yet Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the SEC adopted final rules under SEC Release No. 33-11275, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Enhancement and Standardization of Climate-Related Disclosures for Investors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires registrants to provide certain climate-related information in their registration statements and annual reports. The rules require information about a registrant's climate-related risks that are reasonably likely to have a material impact on its business, results of operations, or financial condition. The required information about climate-related risks will also include disclosure of a registrant's greenhouse gas emissions. In addition, the rules will require registrants to present certain climate-related financial metrics in their audited financial statements. These requirements are effective for the Company in various fiscal years, starting with its fiscal year beginning January 1, 2025. However, the climate rule is currently stayed which could potentially impact the effective date. Disclosures will be required prospectively, with information for prior periods required only to the extent it was previously disclosed in an SEC filing. The Company is currently evaluating the impact of these final rules on its consolidated financial statements and disclosures.</span></div>
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="text-align:justify;text-indent:45pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The presentation of these Condensed Consolidated Financial Statements and accompanying notes in conformity with GAAP require management to make estimates and assumptions that affect the amounts reported, as further described in the Annual Report on Form 10-K for the year ended December 31, 2023. Accordingly, actual results could differ materially from management’s estimates and assumptions.</span></div>
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
201000000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
177000000 usd
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
255695000 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
254392000 shares
CY2024Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2667000 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1778000 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
258362000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
256170000 shares
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.78
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.69
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q1 us-gaap Revenues
Revenues
1622000000 usd
CY2023Q1 us-gaap Revenues
Revenues
1538000000 usd
CY2024Q1 us-gaap Revenues
Revenues
1622000000 usd
CY2023Q1 us-gaap Revenues
Revenues
1538000000 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26000000 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22000000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
5000000 usd
CY2023Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
5000000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0600
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0482
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0412
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0356
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4102
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.4230
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M20D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M20D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5758000000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.20
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
8.51
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1503000000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.80
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.59
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
204000000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
29.34
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
8.27
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7057000000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.43
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
7.68
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6829000000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
29.47
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M23D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3841000000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
32.86
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y9M25D
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
227000000 usd
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M21D
CY2024Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDatePercent
0.05
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
61000000 usd
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
20000000 usd
CY2024Q1 us-gaap Severance Costs1
SeveranceCosts1
23000000 usd
CY2023 us-gaap Severance Costs1
SeveranceCosts1
62000000 usd
CY2024Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
27000000 usd
CY2023 us-gaap Payments For Restructuring
PaymentsForRestructuring
21000000 usd
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
57000000 usd
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
61000000 usd
CY2024Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.147
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.246
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
435000000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
566000000 usd
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
189000000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
110000000 usd
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
673000000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
684000000 usd
CY2024Q1 us-gaap Other Inventory Supplies
OtherInventorySupplies
70000000 usd
CY2023Q4 us-gaap Other Inventory Supplies
OtherInventorySupplies
65000000 usd
CY2024Q1 us-gaap Inventory Gross
InventoryGross
1367000000 usd
CY2023Q4 us-gaap Inventory Gross
InventoryGross
1425000000 usd
CY2024Q1 us-gaap Inventory Lifo Reserve
InventoryLIFOReserve
3000000 usd
CY2023Q4 us-gaap Inventory Lifo Reserve
InventoryLIFOReserve
0 usd
CY2024Q1 ogn Inventory Net And Inventory Noncurrent
InventoryNetAndInventoryNoncurrent
1364000000 usd
CY2023Q4 ogn Inventory Net And Inventory Noncurrent
InventoryNetAndInventoryNoncurrent
1425000000 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
1263000000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1315000000 usd
CY2024Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
101000000 usd
CY2023Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
110000000 usd
CY2024Q1 us-gaap Lifo Inventory Amount
LIFOInventoryAmount
135000000 usd
CY2023Q4 us-gaap Lifo Inventory Amount
LIFOInventoryAmount
105000000 usd
CY2024Q1 ogn Derivative Gain Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag
DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
Foreign currency gain (loss) in Other comprehensive income
CY2023Q1 ogn Derivative Gain Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag
DerivativeGainStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag
Foreign currency gain (loss) in Other comprehensive income
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1000000 usd
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2024Q1 us-gaap Transfer Of Financial Assets Accounted For As Sales Amount Derecognized
TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
51000000 usd
CY2023Q4 us-gaap Transfer Of Financial Assets Accounted For As Sales Amount Derecognized
TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized
66000000 usd
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
79000000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
84000000 usd
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
8714000000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
8760000000 usd
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
9000000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
9000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-36000000 usd
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8705000000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8751000000 usd
CY2024Q1 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
8316000000 usd
CY2023Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
8253000000 usd
CY2024Q1 ogn Debt Instrument Interest Payments
DebtInstrumentInterestPayments
69000000 usd
CY2024Q1 ogn Debt Instrument Average Maturity
DebtInstrumentAverageMaturity
P4Y8M12D
CY2024Q1 us-gaap Long Term Debt Weighted Average Interest Rate Over Time
LongTermDebtWeightedAverageInterestRateOverTime
0.057
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
7000000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9000000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
9000000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
9000000 usd
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
6755000000 usd
CY2024Q1 ogn Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
2004000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
30000000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
30000000 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-36000000 usd
CY2024Q1 us-gaap Litigation Reserve
LitigationReserve
19000000 usd
CY2023Q4 us-gaap Litigation Reserve
LitigationReserve
20000000 usd
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001821825-24-000056-index-headers.html Edgar Link pending
0001821825-24-000056-index.html Edgar Link pending
0001821825-24-000056.txt Edgar Link pending
0001821825-24-000056-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ogn-20240331.htm Edgar Link pending
ogn-20240331.xsd Edgar Link pending
ogn03312024-exhibit311.htm Edgar Link pending
ogn03312024-exhibit312.htm Edgar Link pending
ogn03312024-exhibit321.htm Edgar Link pending
ogn03312024-exhibit322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ogn-20240331_lab.xml Edgar Link unprocessable
ogn-20240331_pre.xml Edgar Link unprocessable
ogn-20240331_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ogn-20240331_cal.xml Edgar Link unprocessable
ogn-20240331_def.xml Edgar Link unprocessable